AML & TREATMENT
WITH TIBSOVO®
About AML
About AML
What is AML?
In healthy bone marrow, essential cells such as red blood cells, white blood cells, and platelets are produced. These specialized cells transport oxygen, help fight infections, and assist in blood clotting.
Acute myeloid leukemia (AML) is a cancer that disrupts this important process. AML affects a type of white blood cell in the bone marrow and blood called a myeloblast. In people with AML, the myeloblasts are immature and abnormal. These cells do not mature or work like they should. As more and more myeloblasts are produced, they prevent healthy cells from forming and working. When there are too many myeloblasts and not enough healthy cells, the symptoms of AML begin to occur.
Types of AML
Newly diagnosed AML means you've never had AML or been previously treated for AML.
Secondary AML (sAML) may occur in individuals who have previously experienced a hematological disorder or developed AML as a result of certain cytotoxic treatments.
Relapsed AML means your AML went away and then came back after a period of remission.
Refractory AML means your AML did not go away completely after initial treatment and is no longer responding to treatment.
Monitor your health. No matter what stage of treatment or remission you are in, it is important to have regular follow-up visits with your healthcare provider.
Types of remission
A goal of cancer treatments is to help get people with cancer into remission. With AML and other blood cancers, there are a few types of remission, including:
- Complete remission (CR) means no signs of cancer are seen, and bone marrow and blood counts have returned to normal.
- Complete remission with partial hematological recovery (CRh) means no signs of cancer are seen, but certain blood counts have not completely returned to normal.
Targeted treatment
HOW TREATMENT FOR NEWLY DIAGNOSED OR RELAPSED/REFRACTORY AML WITH TIBSOVO WORKS
Genetic mutations and targeted treatments
Genetic mutations are changes in the DNA (deoxyribonucleic acid) of a cell. Mutations can play a role in the development of AML. That is why it’s important to get tested for genetic mutations to help your healthcare team understand which AML treatments may work best for you.
TIBSOVO is a targeted therapy that works against a mutation called the IDH1 mutation. The IDH1 mutation plays an important role in the development of AML because it prevents myeloblasts from becoming healthy white blood cells.
About 1 in 6 people with AML have an IDH1 mutation.
As a targeted therapy, TIBSOVO works differently from traditional chemotherapy. Traditional chemotherapy kills cells that divide quickly, including cells in healthy tissues. It is typically given by infusion, usually in the hospital.
TIBSOVO is an oral treatment that can help myeloblasts grow into healthy blood cells by inhibiting mutated IDH1.
Because personalized, targeted therapies can only be used on specific mutations, not all targeted therapies can be used for every patient.
How TIBSOVO works against your AML
TIBSOVO is a targeted therapy. TIBSOVO works on cells with a mutation called an IDH1 mutation. In IDH1‑mutated AML, myeloblasts do not develop into fully formed, healthy white blood cells.
Bone marrow after treatment with TIBSOVO. TIBSOVO targets the mutation causing myeloblasts to remain immature. By targeting the IDH1 mutation, TIBSOVO helps the body return to normal blood cell counts.
TIBSOVO is a targeted therapy. TIBSOVO works on cells with a mutation called an IDH1 mutation. In IDH1‑mutated AML, myeloblasts do not develop into fully formed, healthy white blood cells.
Bone marrow after treatment with TIBSOVO. TIBSOVO targets the mutation causing myeloblasts to remain immature. By targeting the IDH1 mutation, TIBSOVO helps the body return to normal blood cell counts.
TIBSOVO works differently from chemotherapy in that it does not attack normal, healthy blood cells.
TIBSOVO + azacitidine: better together
Your doctor may prescribe TIBSOVO in combination with azacitidine to treat newly diagnosed AML patients who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments. The two treatments work together to extend survival.
Azacitidine is administered by your healthcare provider in an office setting. Please consult your doctor to learn more about this combination regimen.